Search Results for "Lipids"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Lipids. Results 21 to 30 of 33 total matches.

Expanded Table: Some Biologic Drugs and JAK Inhibitors for Rheumatoid Arthritis (online only)

   
The Medical Letter on Drugs and Therapeutics • Nov 15, 2021  (Issue 1637)
; monitoring of CBCs, lipid levels, and liver enzymes is recommended Serious infections ...
View Expanded Table: Some Biologic Drugs and JAK Inhibitors for Rheumatoid Arthritis
Med Lett Drugs Ther. 2021 Nov 15;63(1637):e187-9 |  Show IntroductionHide Introduction

Upadacitinib (Rinvoq): A Second JAK Inhibitor for Ulcerative Colitis

   
The Medical Letter on Drugs and Therapeutics • Sep 05, 2022  (Issue 1658)
. Lipid increases and gastrointestinal perforation have been reported with the drug. Table 4 ...
The FDA has approved the oral Janus kinase (JAK) inhibitor upadacitinib (Rinvoq – Abbvie) for treatment of moderately to severely active ulcerative colitis in adults who have had an inadequate response to or cannot tolerate one or more tumor necrosis factor (TNF) inhibitors. Upadacitinib is the second JAK inhibitor to be approved for this indication; tofacitinib (Xeljanz) was the first. Upadacitinib is also approved for treatment of rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, and ankylosing spondylitis.
Med Lett Drugs Ther. 2022 Sep 5;64(1658):142-4 |  Show IntroductionHide Introduction

Risankizumab (Skyrizi) - An IL-23 Antagonist for Crohn's Disease

   
The Medical Letter on Drugs and Therapeutics • Dec 26, 2022  (Issue 1666)
% with risankizumab 360 mg, and 2.1% with placebo. Lipid elevations have been reported with the drug. Serious ...
The injectable interleukin (IL)-23 antagonist risankizumab-rzaa (Skyrizi – Abbvie) has been approved by the FDA for treatment of moderately to severely active Crohn's disease (CD) in adults. Risankizumab was approved earlier for treatment of plaque psoriasis and psoriatic arthritis.
Med Lett Drugs Ther. 2022 Dec 26;64(1666):205-7 |  Show IntroductionHide Introduction

Clascoterone Cream (Winlevi) for Acne

   
The Medical Letter on Drugs and Therapeutics • Dec 27, 2021  (Issue 1640)
antagonist that inhibits production of lipids and inflammatory cytokines from sebocytes in vitro. J Drugs ...
The FDA has approved Winlevi (Sun), a 1% cream formulation of the androgen receptor inhibitor clascoterone, for treatment of acne vulgaris in patients ≥12 years old. It is the first topical androgen receptor inhibitor to be approved by the FDA.
Med Lett Drugs Ther. 2021 Dec 27;63(1640):202-4 |  Show IntroductionHide Introduction

Expanded Table: Some Drugs for Inflammatory Bowel Disease (online only)

   
The Medical Letter on Drugs and Therapeutics • Jul 10, 2023  (Issue 1680)
tract infection, increased blood creatinine phosphokinase, lipid level increases, rash, acne, headache ...
View the Table: Some Drugs for Inflammatory Bowel Disease
Med Lett Drugs Ther. 2023 Jul 10;65(1680):e115-9   doi:10.58347/tml.2023.1680d |  Show IntroductionHide Introduction

Drugs for Hypertension

   
The Medical Letter on Drugs and Therapeutics • May 27, 2024  (Issue 1703)
55.20 bradycardia and lipid changes Beta-Adrenergic Blockers with Alpha-Blocking Properties Carvedilol ...
American College of Cardiology/American Heart Association (ACC/AHA) guidelines for treatment of hypertension were last published in 2018. Treatment of hypertensive urgencies and emergencies is not discussed here.
Med Lett Drugs Ther. 2024 May 27;66(1703):81-8   doi:10.58347/tml.2024.1703a |  Show IntroductionHide Introduction

Drugs for Menopausal Symptoms

   
The Medical Letter on Drugs and Therapeutics • Mar 04, 2024  (Issue 1697)
supplement on lipid profile, bone mineral density, and symptoms in menopausal women: a randomized, double ...
The primary symptoms of menopause are genitourinary and vasomotor. The genitourinary syndrome of menopause (GSM) includes symptoms such as burning, irritation, dryness, dyspareunia, dysuria, and recurrent urinary tract infection. Vasomotor symptoms (VMS; hot flashes, night sweats) often disrupt sleep.
Med Lett Drugs Ther. 2024 Mar 4;66(1697):33-8   doi:10.58347/tml.2024.1697a |  Show IntroductionHide Introduction

Drugs for Rheumatoid Arthritis

   
The Medical Letter on Drugs and Therapeutics • Nov 15, 2021  (Issue 1637)
tofacitinib levels and should be avoided.31 monitoring of complete blood counts, lipid levels, and liver ...
Rheumatoid arthritis (RA) is prevalent in 0.5% of adults in the US; it is about 2.5 times more common in women than in men. Guidelines for treatment of RA from the American College of Rheumatology were recently updated. The goal of treatment is to minimize disease activity and prevent irreversible joint damage.
Med Lett Drugs Ther. 2021 Nov 15;63(1637):177-84 |  Show IntroductionHide Introduction

Drugs for Inflammatory Bowel Disease

   
The Medical Letter on Drugs and Therapeutics • Jul 10, 2023  (Issue 1680)
, increased blood creatine phosphokinase, lipid level increases, and acne. Serious infections, including ...
Ulcerative colitis (UC) and Crohn's disease (CD), referred to collectively as inflammatory bowel disease (IBD), are chronic immune-mediated inflammatory conditions. Guidelines for treatment of UC and CD have been updated in recent years
Med Lett Drugs Ther. 2023 Jul 10;65(1680):105-12   doi:10.58347/tml.2023.1680a |  Show IntroductionHide Introduction

Comparison Table: Some Oral Antiseizure Medications (online only)

   
The Medical Letter on Drugs and Therapeutics • Aug 05, 2024  (Issue 1708)
syndrome, hyperinsulinemia, lipid abnormalities, hirsutism and menstural disturbances in women ...
View the Comparison Table: Some Oral Antiseizure Medications
Med Lett Drugs Ther. 2024 Aug 5;66(1708):e133-40   doi:10.58347/tml.2024.1708b |  Show IntroductionHide Introduction